[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.90.95. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
November 8, 2006

Risk of Serious Infections and Malignancies With Anti-TNF Antibody Therapy in Rheumatoid Arthritis

Author Affiliations
 

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2006;296(18):2201-2204. doi:10.1001/jama.296.18.2201-a

To the Editor: In their meta-analysis, Dr Bongartz and colleagues1 assessed the risks of infections and malignancies associated with the use of tumor necrosis factor α (TNF-α) antibody therapies in randomized controlled trials of patients with rheumatoid arthritis (RA). Because each original study had few events, answering this question requires pooling the findings of many trials, each of which has limited power to examine adverse event rates.

First Page Preview View Large
First page PDF preview
First page PDF preview
×